サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1609744

日本のがん免疫療法市場レポート：治療タイプ、用途、エンドユーザー、地域別、2024年～2032年

Japan Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 115 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
日本のがん免疫療法市場レポート：治療タイプ、用途、エンドユーザー、地域別、2024年～2032年
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 115 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本のがん免疫療法市場の市場規模は2023年に70億1,510万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに136億3,570万米ドルに達し、2024年から2032年の間に7.5％の成長率（CAGR）を示すと予測しています。同市場は、がん罹患率の増加、政府による支援プログラム、医療保険の普及など、いくつかの重要な要因によって推進されています。

本レポートで扱う主な質問

  • 日本のがん免疫療法市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19の日本のがん免疫療法市場への影響は？
  • 日本のがん免疫療法市場の治療タイプ別の内訳は？
  • 日本のがん免疫療法市場の用途別の内訳は？
  • 日本のがん免疫療法市場のエンドユーザー別の内訳は？
  • 日本のがん免疫療法市場のバリューチェーンにはどのような段階がありますか？
  • 日本のがん免疫療法における主な促進要因と課題は何か？
  • 日本のがん免疫療法市場の構造と主要プレーヤーは？
  • 日本のがん免疫療法市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本のがん免疫療法市場：イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本のがん免疫療法市場情勢

  • 過去および現在の市場動向（2018～2023年）
  • 市場予測（2024～2032年）

第6章 日本のがん免疫療法市場：治療タイプの内訳

  • モノクローナル抗体
  • がんワクチン
  • チェックポイント阻害剤
  • 免疫調節薬
  • その他

第7章 日本のがん免疫療法市場：用途別の内訳

  • 肺がん
  • 乳がん
  • 大腸がん
  • 悪性黒色腫
  • 前立腺がん
  • 頭頸部がん
  • その他

第8章 日本のがん免疫療法市場：エンドユーザー別の内訳

  • 病院
  • がん研究センター
  • クリニック
  • その他

第9章 日本のがん免疫療法市場：競合情勢

  • 概要
  • 市場構造
  • 市場プレーヤーのポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第10章 主要企業のプロファイル

第11章 日本のがん免疫療法市場：業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第12章 付録

目次
Product Code: SR112024A18570

Japan cancer immunotherapy market size reached US$ 7,015.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13,635.7 Million by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. The market is being propelled by several significant factors, including an increasing incidence of cancer cases, supportive government programs, and the widespread accessibility of medical insurance.

Cancer is a medical condition characterized by the uncontrolled growth and spread of certain cells in the body to various parts. Its development is often linked to factors such as alcohol or tobacco consumption, an unhealthy diet, exposure to air pollution, and a lack of physical activity. Individuals affected by cancer can experience significant health challenges, including feelings of anxiety, depression, fear of mortality, pain, stress, and even thoughts of suicide. Immunotherapy is an approach to cancer treatment involving the use of antibodies that bind to and inhibit the activity of proteins produced by cancer cells. This method helps strengthen the immune system's ability to identify and eliminate abnormal cancer cells within the body. Consequently, it finds widespread application in the treatment of various cancer types, including lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers.

Japan Cancer Immunotherapy Market Trends:

In the context of the Japanese market, several significant factors are positively impacting the cancer immunotherapy sector. One of the primary drivers is the rising number of cancer cases, attributed to poor dietary habits and exposure to harmful substances among individuals worldwide. Additionally, there is a growing awareness regarding diverse cancer treatment options among the global population, contributing to market expansion. Furthermore, the increasing adoption of cancer immunotherapies is driven by their ability to offer prolonged progression-free survival (PFS) and overall survival (OS) compared to traditional anti-tumor therapies. The availability and accessibility of medical insurance, alongside rising healthcare expenditure, are presenting attractive growth prospects for industry investors. Moreover, there is a growing demand for treatment approaches with fewer adverse effects, which aligns with the increasing approval of novel immunotherapies and fuels market growth. Government agencies and non-profit organizations in various countries are actively promoting the adoption of cancer immunotherapy through widespread awareness campaigns focused on cancer prevention. Lastly, the market benefits from ongoing technological advancements in cancer treatment therapies, which are enhancing the efficiency of disease management strategies. These factors collectively contribute to the positive growth trajectory of the cancer immunotherapy market in Japan.

Japan Cancer Immunotherapy Market Segmentation:

Therapy Type Insights:

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • Others

Application Insights:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Others

End User Insights:

  • Hospitals
  • Cancer Research Centers
  • Clinics
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan cancer immunotherapy market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan cancer immunotherapy market?
  • What is the breakup of the Japan cancer immunotherapy market on the basis of therapy type?
  • What is the breakup of the Japan cancer immunotherapy market on the basis of application?
  • What is the breakup of the Japan cancer immunotherapy market on the basis of end user?
  • What are the various stages in the value chain of the Japan cancer immunotherapy market?
  • What are the key driving factors and challenges in the Japan cancer immunotherapy?
  • What is the structure of the Japan cancer immunotherapy market and who are the key players?
  • What is the degree of competition in the Japan cancer immunotherapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Immunotherapy Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Cancer Immunotherapy Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Cancer Immunotherapy Market - Breakup by Therapy Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Forecast (2024-2032)
  • 6.2 Cancer Vaccines
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)
  • 6.3 Checkpoint Inhibitors
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2018-2023)
    • 6.3.3 Market Forecast (2024-2032)
  • 6.4 Immunomodulators
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2018-2023)
    • 6.4.3 Market Forecast (2024-2032)
  • 6.5 Others
    • 6.5.1 Historical and Current Market Trends (2018-2023)
    • 6.5.2 Market Forecast (2024-2032)

7 Japan Cancer Immunotherapy Market - Breakup by Application

  • 7.1 Lung Cancer
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Breast Cancer
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)
  • 7.3 Colorectal Cancer
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2018-2023)
    • 7.3.3 Market Forecast (2024-2032)
  • 7.4 Melanoma
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2018-2023)
    • 7.4.3 Market Forecast (2024-2032)
  • 7.5 Prostate Cancer
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2018-2023)
    • 7.5.3 Market Forecast (2024-2032)
  • 7.6 Head and Neck Cancer
    • 7.6.1 Overview
    • 7.6.2 Historical and Current Market Trends (2018-2023)
    • 7.6.3 Market Forecast (2024-2032)
  • 7.7 Others
    • 7.7.1 Historical and Current Market Trends (2018-2023)
    • 7.7.2 Market Forecast (2024-2032)

8 Japan Cancer Immunotherapy Market - Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Cancer Research Centers
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)
  • 8.3 Clinics
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2018-2023)
    • 8.3.3 Market Forecast (2024-2032)
  • 8.4 Others
    • 8.4.1 Historical and Current Market Trends (2018-2023)
    • 8.4.2 Market Forecast (2024-2032)

9 Japan Cancer Immunotherapy Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Company A
    • 10.1.1 Business Overview
    • 10.1.2 Product Portfolio
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Company B
    • 10.2.1 Business Overview
    • 10.2.2 Product Portfolio
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Company C
    • 10.3.1 Business Overview
    • 10.3.2 Product Portfolio
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Company D
    • 10.4.1 Business Overview
    • 10.4.2 Product Portfolio
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Company E
    • 10.5.1 Business Overview
    • 10.5.2 Product Portfolio
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Cancer Immunotherapy Market - Industry Analysis

  • 11.1 Drivers, Restraints, and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix